CaDAnCe-101 (BGB-16673)

A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
621 patients (estimated)
Sponsors
BeiGene
Tags
Bruton's Tyrosine Kinase (BTK) Degrader
Trial Type
Treatment
Last Update
4 months ago
SparkCures ID
1373
NCT Identifier
NCT05006716

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.